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ABSTRACT
BACKGROUND
Maspin is found to be a member of serine protease inhibitor/ non inhibitor
superfamily like plasminogen activator inhibitors 1 and 2 and alpha-1
antitrypsin.[4]The gene for maspin is located on chromosome 18q21.3.It has
been shown to be involved in processes that are important to both tumor growth
and metastasis such as apoptosis, cell invasion and angiogenesis.
This study is aimed to analyse maspin expression in chronic non
neoplastic and  neoplastic colorectal diseases.
AIMS AND OBJECTIVES
1. To study tumor progression in colorectal adenocarcinomas.
2. To evaluate maspin expression and its correlation with clinicopathologic
parameters in chronic non neoplastic and neoplastic colorectal diseases.
3. To evaluate the prognostic value of immunohistochemical expression of
maspin in chronic non neoplastic and neoplastic colorectal diseases.
MATERIALS AND METHODS
 A total of 70 cases including 10 controls (normal colonic mucosa) of non
neoplastic and neoplastic colorectal diseases were used for
immunohistochemical analysis of maspin expression .The cases included are
Non specific colitis, Ulcerative colitis, colorectal adenomas and
adenocarcinomas received in the Department of Stanley Medical College from
the Department of Surgery in the year 2012-2013. The immunoreactivity to
maspin was identified by staining of the cytoplasm. 100 cells were randomly
selected and counted from 5 representative fields
RESULTS
In our study maspin expression was found to be increased in males,increasing
depth of invasion , presence of lymphatic and vascular invasion and poor
survival,thus showing increased expression with increase in aggressiveness of
colorectal cancers.Also increased expression was found in carcinoma compared
to normal colonic mucosa, non specific colitis and ulcerative colitis. No
significance was found to be associated with increasing tumor size or
differentiation of the tumor or presence of liver metastasis. Our study is
comparable with other parallel studies where expression of maspin was studied
in colorectal carcinoma.
CONCLUSION
The expression of maspin with various clinicopathological parameters
was analysed and its importance as a prognostic factor was assessed.To
conclude in our study maspin was found to be associated with increasing
aggressiveness of colorectal cancers.
KEY WORDS : Ulcerative colitis , Adenoma , Colorectal carcinoma,
immunohistochemistry , Maspin.
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1INTRODUCTION
Colorectal carcinoma, Adenoma and Inflammatory bowel
diseases are common in the Western industrialized nations.[1,2,3]
However the prevalence is getting higher in regions such as Asia, Africa
and South America.
The incidence of carcinoma is equal in males and females.[2]
The causes for development of carcinoma are varied and include both
genetic and environmental factors. Epithelial polyps and inflammatory
bowel disease have a definite predisposition to colorectal carcinoma.[2]
This transformation includes mutational activation of oncogenes and
inactivation of tumor suppressor genes.
Maspin is found to be a member of serine protease inhibitor/
non inhibitor superfamily like plasminogen activator inhibitors 1 and 2
and alpha-1 antitrypsin.[4]The gene for maspin is located on
chromosome 18q21.3.It has been shown to be involved in processes that
are important to both tumor growth and metastasis such as apoptosis,
cell invasion and angiogenesis.
               In certain cases maspin was found to be paradoxically
overexpressed in active Inflammatory bowel disease, colitis associated
2dysplasia and it was correlated with high Duke’s classification ,depth of
invasion and high grade tumor budding in colorectal carcinomas,
thereby correlating with its aggressiveness.
 This study is aimed to analyse maspin expression in chronic
non neoplastic and  neoplastic colorectal diseases.
3AIMS AND OBJECTIVES
1. To study tumor progression in colorectal adenocarcinomas.
2. To evaluate maspin expression and its correlation with
clinicopathologic parameters in chronic non neoplastic and
neoplastic colorectal diseases.
3. To evaluate the prognostic value of immunohistochemical
expression of maspin in chronic non neoplastic and neoplastic
colorectal diseases.
4REVIEW OF LITERATURE
Embryology
Divisions of the Gut Tube
 Primitive gut is formed by the cephalocaudal and lateral
folding of the embryoleading to incorporation of  a portion of the
endoderm-lined yolksac cavity  into the embryo .The other portions of
theendoderm-lined cavity namely the yolk sac and the allantois,remain
outside the embryo . The middle part, the midgut, remains  attached to
the yolk sac by means of the vitelline duct whereas in the cephalic and
caudal parts of the embryo, theprimitive gut forms a blind-ending tube,
the foregut andhindgut, respectively.Development of the primitive gut
and its derivativesis  discussed in four sections:  The pharyngeal
gut,whichextends from thebuccopharyngeal membrane tothe
tracheobronchial diverticulum.The foregut thatlies caudal to the
pharyngealtube and extends to the liver outgrowth.  The midgut that
begins caudal to the liver bud and extends to the junction of the
righttwo-thirds and left third of the transverse colon in the adult.
Thehindgut which extends from the left third of the transverse colon to
the cloacalmembrane.
5It is the Mesoderm which dictates the type of structure that will form
through a HOX code.  Differentiation of the various regions of  gut and
its derivatives  dependson a reciprocal interaction between the endoderm
of  guttube and the surrounding splanchnic mesoderm. This HOX code
is similar to the one thatestablishes the anterior and the posterior body
axis. Induction of the HOX code  is  a  result  of sonic hedgehog
(SHH)that isexpressed throughout the gutendoderm. Thus, in the region
of the mid- and hindgut, expression of SHH ingut endoderm leads to a
nested expression of the HOX code in the mesoderm.After themesoderm
gets specified by this code, it instructs theendoderm to form the various
components of the mid- and hindgut regions,which includes the small
intestine, cecum, colon, and cloaca.
 Portions of the gut tube and its derivatives are suspended from
dorsal andventral body wall by mesenteries.Such organs are called
intraperitoneal,whereas retroperitoneal organs are those that lie against
the posterior body wall and are coveredby peritoneum on their anterior
surface only. Peritoneal ligaments are double layers of peritoneumthat
pass from one organ to another or from an organ to thebody
wall.Initially the foregut, midgut, and hindgut are in broad contact with
the mesenchyme of  posterior abdominal wall .By the fifth week, the
6connecting tissue bridge gets narrowed  and the caudal part of the
foregut, the midgut and a major part of the hindgut are suspended from
the abdominal wall by the dorsal mesentery which extends from  lower
end of the esophagus to the cloacal region of the hindgut. In the region
of the stomach it forms the greater omentum;in the region of the
duodenum it forms the dorsal mesoduodenum; andin the region of the
colon it forms the dorsal mesocolon. Dorsal mesentery of the jejunal
and ileal loops forms the mesentery proper[5]. Mesenteries and
ligaments  provide pathways for vessels, nerves,and lymphatics to and
from abdominal viscera.
7Anatomy
The adult human esophagus measures 40 cms from incisor teeth to the
gastro esophageal junction. The upper esophageal sphincter is at the
level of cricopharyngeal muscle. The lower esophageal sphincter is 2 to
3 cms above the gastroesophageal junction. The stomach is a sacular
organ with potential capacity of 3000 ml. It begins at the gastro
esophageal junction and ends at the pylorus where the muscles get
thickened to form the pyloric sphincter.The small intestine is 6 metres in
length. It begins with the duodenum which is retroperitoneal and
extends for about 25 cms and then continues as the jejunum which
enters the peritoneal cavity till the ileoceacal valve where it transforms
into colon and becomes retroperitonal again.
The colon
              The colon is composed of Ceacum, ascending colon, transverse
colon and descending colon. The ceacum and ascending colon are
covered on their ventral surfaces by peritoneum but posteriorly they are
directly fixed to the posterior abdominal wall. The transverse colon
extends from the hepatic flexure to the splenic flexure and gets
suspended by the lesser omentum. The descending colon is  adherent to
8the posterior abdominal wall. The sigmoid colon is the only portion of
colon which is suspended by the mesentery and begins as the pelvic
brim. It then continues as the rectum which ends with the anal canal.[6]
9Physiology
The main function of GIT is to help the body to absorb
nutrients, water, vitamins and minerals. So predominantly the entire
work of the Gastro intestinal system is divided into digestive work and
absorption of products of digestion.The digestive process is
accomplished by mechanical and chemical means. The mechanical
means includes the acts of  chewing ,swallowing and movements of
GIT. The chemical means are achieved by saliva , gastric juice , bile
juice and intestinal juice .
 The large intestine predominantly involves mixing movements
due to the haustrations for exposure of the feacal material to the surface
of the large intestine.The propulsive movements help in transporting the
fecal material further down the colon . Gastrocolic and duodenocolic
reflexes helped in distension of stomach and duodenum and further
initiation of mass movements.
 The distention of rectum is brought about by defecation reflex
which generates a pressure of 50 – 60 mm Hg . This reflex is caused by
activation of parasympathetic nerve fibres which cause relaxation of
internal anal sphincter. Finally,Voluntary relaxation of the external anal
10
sphincter associated with increased pressure of the abdominal wall
muscles cause the act of defecation.[7]
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Histology
The histology of the colon is such that it can perform its
principal function of  absorption  of salt and water from the feces and
propulsion of solid feces to the rectum before defecation.The layers of
large intestine includes the four layers – Mucosa which is further
subdivided into epithelium, lamina propria and muscularis mucosae,
Sub mucosa, Muscularis propria and the serosa.The muscularis layer is
divided into inner circular and outer longitudinal bands. The
longitudinal layer is further divided into three longitudinal bands called
the teania coli. Teania coli are not found in the rectum.
 The mucosa forms longitudinal folds of columns of morgagni
immediately above the anal valves.The mucosa consistes of two types of
cells (i) Absorptive cells and (ii) the mucus secreting goblet cells. They
are arranged in straight tubular glands or crypts which extend upto the
muscularis mucosae. The alcian blue stain can be used to differentiate
between the two. The  goblet cells stain greenish blue whereas the
absorptive cells do not take up any color.
The rectal mucosa has more number of goblet cells compared
to the rest of the intestine.At the recto anal junction the branched
12
circumanal glands open at the distal end of columns of morgagni into
small pits. The anal canal forms last 2-3 cms of the Gastrointestinal tract
and here the stratified squamous epithelium transforms to skin
containing sebaceous and large apocrine sweat glands.[8]
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Pathology:
Inflammatory bowel diseases :
With the increasing use of flexible sigmoidoscopy and
colonoscopy pathologists have  an increasingly important role in the
diagnosis of colitis. Before we go into the pathology of inflammatory
bowel disease, following is a brief introduction to the normal findings in
intestinal mucosa.
 The luminal surface is straight and the Colonic tubules are
found to be tightly packed, parallel and are nonbranching. Goblet cells
are numerous. These glands are  closely associated with  the muscularis
mucosae. The appearance can be equated to test tubes in a rack. The
lamina propria contains a mixed inflammatory cell infiltrate, including
plasma cells, lymphocytes, eosinophils, and macrophages which are
proportionately less in number.
 Rarely an intraepithelial lymphocyte can be present. The
muscularis mucosae is thin. The submucosa is generally devoid of
inflammation. Scattered intramucosal lymphoid follicles can be
encountered, mainly in younger individuals. The architecture may be
distorted in areas of lymphoid follicles, the muscularis mucosae may be
incomplete and some of the lymphoid follicles may spill over into the
14
submucosa. Overlying the lymphoid aggregates are flattened surface
cells called M cells. In this M-cell region, the epithelium normally
contains more number of mononuclear inflammatory cells, and the
amount of intraepithelial mucin is decreased .Paneth cells are considered
a normal finding only in the cecum and the proximal ascending colon.[9]
 Inflammatory bowel diseases includes those disorders which
cause inappropriate mucosal immune response againstnormal
commensal bacteria. This is supported by the theory of hygiene
hypothesis which states that better storage of food and decreased
contamination of food leads to overwhelming immune response to
normal commensals in susceptible individuals because of inadequate
regulatory processes.[10] Two conditionsare predominantly included in
this– Crohn’s disease and Ulcerative colitis. Our major concern is
Ulcerative colitis as it has more potential to transform into malignancy
than Crohn’s disease.Hence cases of Ulcerative colitis have been
included in the study. The following is a brief outlook on the
pathogenesis, gross, microscopic picture and the course of the disease.
15
Pathogenesis
Genetic factors : Polymorphisms in NOD2, IRGM (immunity related
GTPase M) and ATG16L1 (Autophagy related 16 like) are found to be
responsible for increasing inflammatory activity and abnormalities in the
epithelial barrier mechanisms. These changes are more related to
Crohn’s than Ulcerative colitis.
Mucosal immune Responses : Th1,  Th17 are involved in the immune
dysregulation in  Crohn’s as well as Ulcerative colitis. Hence mutations
in IL-23 seems to confer some protection in both these conditions. Also
Th2 seems to be involved in Ulcerative colitis due to increasing IL-13
activity associated with it.
Epithelial defects : Mutation of organic cation transporter and mutation
of extracellular matrix protein 1 which inhibits matrix
metalloproteinases-9 are associated with Ulcerative colitis.
Microbiota: Antibodies against bacterial protein flagellin are associated
with colitis manifestations.[11]
16
Ulcerative colitis : More commonly is associated with malignant
potential that Crohn’s disease. Ulcerative colitis occurs with equal
frequency in both sexes. It appears most often in patients between
20 and 30 years of age, with a second peak between 70 and 80 years.
Ulcerative colitis is characteristically a left-sided disease, which usually
begins in the rectosigmoid area.
 Grossly the mucosa is red and granular and has broad based
ulcers. The ulcers are longitudinal and not serpentine like in Crohn’s
disease. Pseudopolyps and mucosal regenerative bridges are present.
Mucosal atrophy takes place in chronic conditions and damage to the
muscularis propria disturbs the neuromuscular function and leads to
toxic megacolon.[12]
 Microscopic finding shows dense lymphoplasmacytic infiltrate
in mucosa and submucosa. Architecturally distorted glands containing
intraepithelial and luminal lymphocytes indicating cryptitis and crypt
abcess.[13]The density of neutrophils is similar throughout the mucosa
and submucosa leading to equalized mucin depletion and occasional
crypt rupture can lead to accumulation of histiocytes and giant cells can
result in mucin granulomas which are different from those seen in
Crohn’s disease.[14]In fulminant diseases the inflammation may extend
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beyond muscularis mucosa. Crypt architectural distortion,basal
plasmacytosis,paneth cell metaplasia and basally located lymphoid
aggregates are considered as markers of previous significant crypt
injury.Hence these are considered as markersof chronic colitis.[15]
Patients with Chronic Ulcerative colitis are at an increased risk
for dysplasia and then transformation to adenocarcinoma.[16,17,18] The
biopsy specimens are classified into the following three groups
depending upon the changes present :
1.Positive
2. Negative
3. Indefinite for dysplasia
 Positive dysplasia is further classified into high grade and low
grade dysplasia depending upon extent of dysplastic changes. Low grade
dysplasia is limited to the lower half of the epithelium whereas high
grade dysplasia extends to the luminal side of the epithelium with
increased  stratification, cytologic atypia and loss of nuclear polarity.
Indefinite for dysplasia is further divided into probably
dysplastic, probably inflammatory  and unknown[16]. Hence the need for
endoscopic surveillance in long standing cases of Ulcerative colitis.This
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dysplasia can be present in a flat mucosa or mucosa with villous
configuration or mucosa with nodular growth[16].
The following is the standard surveillance protocol for colitis
patients which has been widely recommended[17,19,20].
Table 1
Mucosal Ulcerative Colitis and Dysplasia: Management Based on
Biopsy taken for surveillance
Biopsy
Interpretation
Recommendation
Negative for
dysplasia
Regular follow-up to be continued
Indefinite for
dysplasia
Follow-up for short term.
Positive; low-
grade dysplasia
Follow-up for short term; some recommend
colectomy; others consider colectomy if associated
with suspicious gross lesiona
Positive; high-
grade dysplasia
colectomya to be considered
19
Adenomas
Table 2
Classification of Serrated Colonic Polyps
I. Nondysplastic Serrated Polyps
A. Normal architecture, normal proliferation
1. Microvesicular hyperplastic polyp
2. Goblet cell hyperplastic polyp
3. Mucin-poor hyperplastic polyp
B. Abnormal architecture, abnormal proliferation
1. Sessile serrated polyp
II. Dysplastic Serrated Polyps
A. Sessile serrated polyp with dysplasia (mixed polyp,advanced
sessile serrated polyp)
B. Serrated adenoma (traditional)
C. Conventional adenoma with serrated architecture
III. Unclassifiable Serrated Polyp (either with or withoutdysplasia)
This study  includes adenomatous polyps as these polyps are
characterized by dysplasia and hence have more chances of progression
to adenocarcinoma.
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Adenomas are mainly classified into conventional, serrated or
flat.Conventional adenomas are further classified into tubular,
tubulovillous and villous adenomas.When multiple adenomas are
present it may indicate a genetic syndrome (FAP, attenuated FAP,MYH-
associated polyposis syndrome). Prevalence increases after the age of 40
years.[21]The presence of one adenoma is associated with
40–50% increased risk of additional adenomas.The risk for new
adenomas is 30-60% after polypectomy for initial adenoma.[21]
 Clinically most patients have rectal bleeding.Hence Large
polyps can cause  iron deficiency anemia[22].
Grossly adenomas are exophytic mucosal protrusions.Large
adenomas can be hemorrhagic and adenomas larger than 2 cms are more
likely for malignant transformation than smaller adenomas.[23]
Microscopic description: The villous type of adenoma is
characterized by more than 75% villous architecture and the tubular type
by less than 25% villous architecture. Hence the tubulovillous type has
between 25–75% villous architecture.Adenomas are typically
characterized by the presence of dysplasia.It can be high grade or low
grade. High grade dysplasia have significant pleomorphism, increase in
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mitotic activity,numerous atypical mitoses and increased loss of
polarity. Architectural changes such as back-to-back gland configuration
and cribriforming can also be noted. With progression of
neoplasia,glandsbecome more irregular and complex and lose their
orderly configuration. In addition, neoplastic nuclei become more
“open” in appearance and may contain prominent nucleoli.Intramucosal
adenocarcinoma show invasion into the lamina propria which will not be
present in high grade dysplasia[24].
 True adenomas which are characterized by serrated adenomas
are more commonly left sided .The lining cells show high nuclear to
cytoplasmic ratio with abundant mucin, high nuclear pleomorphism and
increased mitotic activity.[25]
 The evaluation of an endoscopically removed malignant polyp
is a stepwise process that involves
(a) adequate fixation,
(b) sectioning,
(c) knowledge of the type of removal,
(d) examination of slides, and
(e) pathologist-clinician interaction.
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When examining the slides, one should evaluate and report on the
following:
(a) status of resection margin
(b) grade of cancer, and
(c) presence or absence of lymphatic or venous invasion.
As the treatment varies depending upon the presence or absence of the
above factors. Presence of lymphatic invasion will lead to conversion of
polypectomy to extended colectomy to prevent further spread of the
disease.[26] Biologically, adenomatous growth is thought toprogress
sequentially, through a continuum: lowgrade dysplasia, high-grade
dysplasia, carcinoma insitu, intramucosal carcinoma, and invasive
carcinoma.[27]
 Some of the syndromes associated with adenomatous polyps
include Familial adenomatous polyposis, Turcot’s syndrome and
Gardner’s syndrome.
23
Adenocarcinoma
Adenocarcinomas of the colon and rectum are more common
in the industrialized countries than in other developing countries. Asia
stands as a low risk region when it comes to this malignancy. Colorectal
carcinomas occur with equal frequency in both men and women and the
mean age of occurrence is found to be 62 yrs.[28] Although in the
developing countries it can be found from 50 yrs of age.[29]Carcinomas
occurring in distal colon and rectum are found to be more aggressive
compared to those occurring in other regions.[28]
The risk factors for occurrence of colorectal carcinomas are found
to be the following-
Table 3[30]
The risk factors for occurrence of colorectal carcinomas
Relative risk
Family history 1.8
Physical inactivity 1.7
Inflammatory bowel disease 1.5
Obesity 1.5
Red meat 1.5
Smoking 1.5
Alcohol 1.4
High vegetable consumption 0.7
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 Other causes include oral contraceptive use, estrogen
replacement and pelvic irradiation. Consumption of Non steroidal anti-
inflammatory agents seems to have a protective effect by interfering
with prostaglandin homeostasis in colorectal cancers. Certain
polymorphisms in enzymes can have protective or deleterious effects on
colorectal carcinomas.
 The genetic syndromes that have association with colorectal
carcinomas include the following :
1. Hereditary non polyposis colorectal cencer syndrome with
mutations in the DNA repair genes including MSH2,MSH6,
MLH1.
2. Familial Adenomatous polyposis syndrome and Attenuated
familial adenomatous polyposis syndrome that includes mutations
in the APC gene.
3. Torre-Muir syndrome that is associated with several
keratoacanthomas and sebaceous tumors[31]
4. Certain other syndromes includes Juvenile polyposis syndrome,
Cowden syndrome, Puetz jeghers syndrome with an attributable
risk of much less that 0.5 %.[32]
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Pathogenesis
The occurrence of colorectal carcinomas is associated with
certain genetic abnormalities like genomic instability that leads to
chromosomal alterations and microsatellite instability that is caused by
mismatch DNA repair.
 The progression of adenoma to carcinoma is characterized by
the following changes :
Initially the normal epithelium undergoes a 5q mutation that
leads to formation of hyperproliferative epithelium then it undergoes
DNA hypomethylation to progress to a low grade adenoma then it
undergoes mutation in 12p or KRAS to progress to an intermediate
adenoma. Mutation or loss of 18q leads to development of a high grade
adenoma. Ultimately mutation in 17p and p53 leads to carcinoma and
later on other accumulated mutations leads to metastasis.[33]
Clinical Presentation : The most common form of presentation is
anemia. Right sided tumors bleed easily and thus present with anemia
compared to left sided tumors that cause changes in bowel habits and
can lead to melena.[34]Other than that patient can develop fever, malaise,
weight loss and abdominal pain.
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Gross: All tumors which are within 15 cms of the anal verge and in the
non peritonalised portion of the left colon are considered to be rectal in
origin. Most of the tumors are rectosigmoid in origin. The varied gross
appearances can be:
1. Bulky polypoid and exophytic tumors
2. Infiltrating and ulcerating tumors
3. Constricting tumors that produce proximal dilatation of the colon
4. Diffuse tumors like linitis plastica
Microscopic features : This neoplasm is characterized by malignant
glands invading the submucosa from the muscularis mucosae. The
glands are lined by malignant columnar epithelial cells.
Adenocarcinoma is further graded :
Grade 1 : Glands forming more than 95 % of the tumor
Grade 2 : Glands forming 50 – 95 % of the tumor
Grade 3 : Glands forming 5-50 % of the tumor
Grade 4 – Glands forming less than 5 % of the tumor
 By default Signet ring cell carcinoma and Mucinous
carcinoma are included in Grade 3 or Poorly differentiated
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category.Medullary carcinoma, Undifferentiated carcinoma and
Carcinosarcoma, Adenosquamous carcinoma are other histological
types. Other rare histopathological variantsof colorectal carcinoma
include pleomorphic (giant cell) type, choriocarcinoma,pigmented, clear
cell, stem cell, andPaneth cell-rich (crypt cell carcinoma).Mixtures of
these variants can be seen.[35]
 As this paper deals with the prognostic significance of maspin
in colorectal diseases, a brief review about some of the other factors that
play a major role in determining the prognosis-
Factors associated with poor prognosis include :
1. Age : Tumors in very young and in very old age groups
2. Sex : Tumors in males
3. CEA levels : > 5 ng / dl are associated with poor prognosis
4. Tumor location : This concept is controversial but one large
study concluded that tumors in the rectum and sigmoid are
associated with worse prognosis compared to tumors in right
colon.[36] Another study stated that tumors in the left colon are
associated with a higher rate of recurrence compared to other
tumors.[37]
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5. Obstruction and perforation : Are  associated  with  poor
prognosis
6. Tumor local extent : Tumor extending beyond bowel wall and to
the adjacent lymph nodes have a poor prognosis
7. Tumor edge : Advanced tumors with  a non polypoid edge are
said to have a poor prognosis
8. Tumor Budding : Tumor cells > 5 at the invasive tumor front are
said to have poor prognosis
9. Vascular invasion,Perineural spread, Pericolonic tumor
deposits are said to have poor prognosis
10. Tumor thickness : Thickness of the tumor at the central
depressed area is said to predict the presence of metastasis and
lymph node involvement
11. Tumor angiogenesis
12. Positive surgical margins and in rectal adenocarcinomas
presence of tumor less than 2mm from the circumferential margin
is associated with poor prognosis.
13. Microscopic tumor type : Signet ring cell carcinoma, Mucinous
carcinoma and Anaplastic carcinomas are associated with poor
prognosis.
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14. Microacinar morphology is associated with poor prognosis
15. Mucin related antigens : Sialyl Tn, Sialyl Lewis are associated
with a  more aggressive course.
16. Fascin is associated with poor prognosis
17. pRB,P16INK4,KRAS, DNA aneuploidy, Claudin 1 expression
and allelic loss of chromosome 18q are associated with poor
prognosis.
18. Lymph node involvement and high microscopic grade and
stage are associated with poor prognosis.
Some of these factors would be assessed in the present study
along with maspin expression.
Factors responsible for good prognosis include the following :
1. Sex :  Females have a better prognosis
2. Margins and inflammatory infiltrate : presence of pushing
margins and a predominant inflammatory infiltrate at the
periphery of the tumor is associated with a better prognosis.
3. HLA-DR expressions, Bcl2 Expression and TGF beta 1
mutations are all associated with better prognosis.
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4.  Pattern of lymph node reaction : Those patients in whom the
lymph nodes show a predominant cell mediated immune reaction
characterized by prominent immunoblasts and sinus histiocytosis
have a better survival rate than others.[38]
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ADENOMA CARCINOMA SEQUENCE
General points in favour of the transformation :
Clinical Evidence of the sequence
• Adenomas and Carcinomas are known to exist in Parallel.
• Adenomas are found in patients who are 7 to 8 years younger than
the carcinoma patients.
• Resected Carcinomas are found contiguous with, Benign
adenomatous tissue.
• Adenomas precede Carinomas in pts with FAP and HNPCC and
are found to have the same general histology as found in isolated
sporadic carcinomas.
Figure 1 : Picture in the left showing benign polyps and Picture
in the right shows the same polyp which has progressed to
cancer as it was not resected.
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The events associated with transformation of adenoma to
carcinoma are distinct molecular alterations associated with
 Well characterized series of histopathologic events.
? Sporadic colorectal carcinoma (CRCs) can be subclassified
into three types based upon the following genetic
abnormalites:
(A) Microsatellite instability / MSI
(B) Chromosomal instability / CIN
(C) An additional group with CpG island methylator phenotype
/ CIMP
Figure 2 : An overview of the mutations that occur
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(A) Chromosomal instability pathway
? Carcinomas arise from the accumulation of activation (by
mutation) and inactivation of  oncogenes and tumor-suppressor
genes respectively  that initially cause adenomatous polyps;then
some acquire additional mutations and become malignant. A total
of 4-10 mutations are required to produce malignancy.
? APC gene mutation  is the earliest event .(germline mutations of
APC are responsible for familial adenomatous polyposis (FAP)
syndrome, while somatic mutations of APC occur in 50% of
sporadic adenomas and 80% of sporadic colon cancer)
? DCC (Deleted in colon cancer) gene loss occurs later in
carcinogenesis . It is frequently deleted in carcinoma (73%) and a
lower percentage is associated with   high grade adenoma (47%).
? K-ras mutations (10% of adenomas, 50% of adenomas with
severe dysplasia, 35-45% of carcinomas) occur in larger polyps.
? KRAS  is  the  downstream  effector  of  EGFR,  and  hence  in
colorectal cancer, the mutational status of KRAS has become an
important predictive marker for the effectiveness of
chemotherepeutic drugs for metastatic colorectal cancers
? p53 gene mutation  is found in 50% of adenomas with high grade
dysplasia and 70% of sporadic colon cancers
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? Loss of the wild type of p53 activity leads tofailure of response to
radio- and chemotherapy.
? DPC4/DCC/SMAD4 mutation (18q21, reduced expression in
70% of carcinomas) which occurs later in the sequence indicates
advancing malignant phenotype.
? Loss or low level of SMAD4 expression in colorectal carcinomas
is associated with poor prognosis.
? EGFR, a receptor tyrosine kinase, overexpression is seen in up to
80% of colorectal cancers and is associated with poor prognosis.
? Screening Colonoscopy to remove adenomas reduces the
incidence of colorectal cancer.
? Polyposis syndrome patients and Villous adenomas have an
increased risk for carcinoma (nearly 100% for familial polyposis
and Gardner’s syndrome).
? Polyps which have no malignant risk are the following:
solitary hyperplastic polyps,
juvenile polyps and
Peutz-Jegher polyps
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Figure 3 : Sequence of events after the earliest APC mutation
(B) Microsatellite instability pathway
? Is found to be associated with inactivation of DNA mismatch
repair proteins and 15–20% of sporadic CRCs are found to  have
microsatellite instability (MSI-H).
? In sporadic colon carcinoma, MSI is  caused by loss of expression
of MLH1, secondary to MLH1 promoter methylation, while in
hereditary nonpolyposis colon cancer / HNPCC inherited
mutation of a repair gene is the cause.
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? Sporadic MSI-H cancers are usually poorly differentiated,
mucinous and more proximally located than HNPCC tumors
? BRAF mutations can also be  associated with the microsatellite
instability pathway
(C) CpG island methylator pathway (CIMP)
? CIMP appear to be an independent predictor for microsatellite
status.One third of CpG island methylator phenotype underlies
microsatellite instability
?  It is also strongly associated with BRAF mutation.
Figure 4 : Formation of adenoma from aberrant crypt focus to
development of carcinoma.
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Serrated Adenoma Pathway:
? Historically, hyperplastic polyps were usually notconsidered a
precursor of carcinoma
? More recent studies have demonstrated that certain types of
hyperplastic or serrated polypsmay give rise to cancer
? Sessile serrated adenomas are commonly found to have BRAF
mutations  in  about  78  %  of  the  cases.  Few  cases  have   K-ras
mutations  amounting to about 11%, in contrast to hyperplastic
polyps, showing frequent K-ras mutations( 80 %)in comparison to
BRAF mutations (20%)
? MLH1 promoter methylation can also be found in  serrated
polyps, suggesting that they give rise to sporadic colorectal
carcinoma with MSI.
? Smoking and estrogen withdrawal may be associated with serrated
pathway carcinoma.
38
Figure 5 : Summary of all the mutations that occur
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Staging of colon cancers
1. AJCC staging of colon cancers:
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
Tis Carcinoma in situ: intraepithelial or invasion oflamina
propria*
T1 Tumor invades submucosa
T2 Tumor invades muscularis propria
T3 Tumor invades through the muscularis propriainto the
subserosa, or into non-peritonealizedpericolic or perirectal tissues
T4 Tumor directly invades other organs orstructures, and/or
perforates visceralperitoneum.
Regional lymph node status
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastases
N1 Metastases in 1 to 3 regional nodes
N2 Metastases in 4 or more regional nodes
     Metastases
MX Distant metastases cannot be assessed
M0 No distant metastases
M1 Distant metastases
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Residual tumor assesment
RX Presence of residual tumor cannot be assessed
R0 No residual tumor
R1 Microscopic residual tumor
R2 Macroscopic residual tumor[39]
Table 4: Staging of colon cancers[40]
American Joint Committee on
Cancer
Dukes
Staging
Modified Astler-Coller
Classification
Stage 0: Tis, N0, M0 A A
Stage I: T1, N0, M0 or
T2, N0, M0
A A/B1
Stage IIA: T3, N0, M0 B B2
Stage IIB: T4, N0, M0 B B2
Stage IIIA: T1-2, N1, M0 C C1
Stage IIIB: T3-4, N1, M0 C C2
Stage IIIC: T any, N2, M0 C C1/C2
Stage IV: T any, N any, M1 D D
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2.Dukes staging :
? Dukes' A: Invasion into but not through the bowel wall.
? Dukes' B: Invasion through the bowel wall but not involving lymph
nodes
? Dukes' C: Involvement of lymph nodes
? Dukes' D: Widespread metastases
3.Astler Coller staging :
Stage A: Limited to mucosa
? Stage B1: Extending into muscularis propria but not penetrating
through it; nodes not involved
? Stage B2: Penetrating through muscularis propria; nodes not
involved
? Stage C1: Extending into muscularis propria but not penetrating
through it. Nodes involved
? Stage C2: Penetrating through muscularis propria. Nodes involved
? Stage D: Distant metastatic spread
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While reporting  colorectal cancer , following parameters should be
examined and reported :
? Location of tumor
? Size and configuration of the cancer
? Status of resection margins
? Grade of the cancer and type of cancer (e.g., typical, mucinous,
small cell)
? Status of lymph nodes :
o Total number of lymph nodes found
o Number of lymph nodes involved (pNx, 0, 1, 2)
? Depth of penetration, including direct extension into other organs,
if present (pT0, 1, 2, 3, 4)
? Status of veins with regard to tumor invasion:
o Intramural veins
o Extramural veins (thick walled or thin walled)
? Presence or absence of lymphatic invasion
? Other lesions present (e.g., adenoma, hyperplastic polyp)
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Maspin expression in colonic diseases :
 Maspin  belongs to serine protease inhibitor / non inhibitor
superfamily. Its gene is located on chromosome 18 and was first
identified in 1994.Maspin expression has been found to be down
regulated in breast, prostate, gastric cancers and upregulated in
pancreatic, colorectal and gall bladder cancers. Our study is focused on
the expression of maspin in colorectal cancers and studying its
significance.
 Maspin  is found to exhibit suppressing activity against tumor
growth and metastasis. Hence it is often silenced in tumors. Maspin has
been shown to be involved in processes such as cell invasion,
angiogenesis  and also apoptosis.
Cao et al. had investigated the relationship between chronic
inflammatory states and neoplasia in 125 specimens. His cases under
study included inflammatory bowel disease (IBD) with different grades
of dysplasia and also  invasive colorectal cancer.His study led to the
discovery that  Maspin was paradoxically over-expressed in both active
IBD and colitis-associated dysplasia compared to inactive IBD or
normal colonic mucosa. This finding suggested that maspin might have
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a  potential role in disease “flare” and neoplastic progression [41].
Umekita et al. had studied expression of maspin in colorectal
adenocarcinomas from 104 patients. His observations concluded that
maspin expression significantly correlated with the higher Dukes’
classification, depth of invasion and highgrade tumor budding. These
results suggest that the expression of maspin may  be associated with the
aggressiveness of colorectal adenocarcinomas.[42] Fung et al. examined
450 resected colorectal cancers . His study also concluded that maspin
has a stronger expression in high-grade tumors [43].
 Again Dietmaier et al. investigated maspin expression in 172
primary stage III colon cancers . His study showed significant treatment
benefit from 5-FU-based chemotherapy in patients with Maspin
expression in primary tumors. These data couldbe useful, if confirmed in
a prospective study, to select patients to receive 5-FU treatment or an
alternative (non-5-FU based) adjuvant therapy .[44]
Hence the present study will be verifying these statements and
attempting to find a relationship between maspin expression and the
prognosis of colorectal cancers.
45
Immunohistochemistry:
Immunohistochemistry involves two disciplines –
immunology and histology.
Immunohistochemistry is used to determine expression of
particular antigen and its microanatomic location in the tissue. IHC uses
antibodies to distinguish antigenic differences between the cells.These
differences can specifically identify the lineage of cell populations and
define biologically distinct population of cells within the same lineage.
 Antigen retrieval technique was introduced by Shi and
associates in 1991. It’s a simple method that involves heating paraffin
sections to a high temperature before IHC staining.The use of antibody
in IHC depends on sensitivity and specificity of antigen antibody
reaction and the hybridoma technique provides limitless source of
highly specific antibodies.
Detection systems :
Antibodies are labeled or flagged by some method to permit
visualization – these include fluorescent substances, enzymes forming
colored reaction with suitable substrate (light microscopy) or heavy
metals (electron microscopy).
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Methods of IHC
Direct conjugate labeled antibody method
 Antibody is attached with a label by chemical means and
directly applied to tissue sections. It is a rapid and easy procedure and
involves detection of multiple antigens which require separate
incubation with specific antibodies.
Indirect sandwich method
Enzymes are labeled with secondary antibody which is produced
against primary antibody.The advantages are increased versatality, high
working dilution of primary antibody and easy preparation of secondary
antibodies against a primary antibody of different species.
Unlabelled antibody methods
Enzyme bridge technique
Here the labeled moiety is linked to the antigen solely by
immunologic binding.
Peroxidase antiperoxidase method :
 The principle of the PAP method is similar to that of the
enzyme bridge method. The acronym PAP denotes the peroxidase
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antiperoxidase reagent that is composed of antibody against horseradish
peroxidase antigen in the form of an immune complex which is small
and stable.Available evidence suggests that this immune complex is
made up of  two antibody molecules and three horseradish peroxidase
molecules. The PAP reagent and the primary antibody must be derived
from the same species (or it can also be from closely related species
with common antigenic determinants),whereas the bridge or linking
antibody is derived from a second species and has specificity against the
primary antibody.
Avidin biotin technique
The high affinity between biotin and avidin is used in this
technique; Biotin binds to the primary antibody and avidin binds to the
enzyme thus attaching it to the biotinylated antibody. Disadvantage of
this procedure is the presence of endogeneous biotin activity that
produces non specific background staining.
Avidin biotin conjugate procedure
                   Here the primary antibody is added followed by biotinylated
secondary antibody and next preformed complexes of avidin and biotin
horse radish peroxidase conjugate.
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Biotin Streptavidin system
               Streptavidin is used in place of avidin. Streptavidin complexes
are more stable compared to avidin.
Immunogold silver technique
This is used in ultrastructural immunolocalisation. Gold
particles are enhanced by addition of several layers of silver.
Polymeric method
This technique allows a large number of enzyme molecules to
be bound to a secondary antibody via dextran backbone. The advantages
of this technique are increased sensitivity in identifying the antigen ,
minimal non specific background staining and decreased number of
assay steps.
Alkaline phosphatase and antialkaline phosphatase method
The principles are same as that of PAP method.
Tissue fixation, Processing and antigen retrieval techniques
Tissues for IHC undergo fixation , dehydration and Paraffin
embedding.
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Fixation
This is a critical step as preservation of morphology is
essential for interpretation. 10 % neutral buffered formalin is used.It has
the following advantages :
1. Good morphological preservation
2. Cheap, easily available, penetrates tissues well and sterilizes them.
3. Carbohydrate antigens are better preserved and does not interfere
with the staining process.
The disadvantage of masking antigens during fixation can be
overcome by antigen retrieval technique.
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Antigen retrieval
 The following techniques are used for unmasking of the
antigen
1. Proteolytic enzyme digestion method
2. Microwave antigen retrieval
3. Pressure cooker antigen retrieval
          4.   Microwave and trypsin antigen retrieval technique
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MATERIALS AND METHODS
Source of data
 A total of70 cases including 10 controls (normal colonic
mucosa) of non neoplastic and neoplastic colorectal diseases .The cases
included are Non specific colitis, Ulcerative colitis, colorectal adenomas
and adenocarcinomas received in the Department of Stanley Medical
College from the Department of Surgery in the year 2012-2013.
Inclusion criteria
All patients diagnosed to have chronic  non neoplastic and
neoplastic  colorectal diseases diagnosed by biopsies as well as
colectomy specimens are included in the study.
Method of data collection
All colorectal biopsies,colectomy and hemicolectomy
specimens were included in the study. Appropriate tissues were sampled
and processed. Sections were cut at 5 microns and stained by H & E
technique and examined under the microscope for adequacy and
appropriate photomicrographs were taken. All the selected cases were
included in the immunohistochemical analysis to study Maspin
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expression. Only 70 cases were studied due to the cost effectiveness of
the immunohistochemical study.
Method of tissue preparation for IHC
10 % buffered formalin was used to fix the tissues. Then the
tissues were processed in various grades of alcolhol and xylol using
automated histokinette.Paraffin blocks were prepared and 5 micron
thickness sections were cut and stained using H& E. Suitable blocks
were chosen for IHC.
 Sections for immunohistochemistry were also cut in the semi
automated microtome.These sections were 4 microns thick and
positively charged slides were used . Sections were subjected to antigen
retrieval technique by pressure cooker method using TRIS EDTA (Ph 9)
buffer solution and then treated by HRP (horse radish peroxidase)
polymer technique.
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HRP polymerTechnique
1. The sections were deparrafinised in xylene or xylene substitutes
2. Rehydrated through graded alcohols
3. The slides were then washed in running tap water
4. The antigen retrieval was performed using the appropriate buffer
by pressure cooker method.
5. The endogeneous peroxide was blocked using peroxidase block
for 5 mins
6. Slides were then washed in 2 changes of TBS buffer for 5 mins
each.
7. Slides were then incubated with protein block for 5 mins
8. Then slides were washed in 2 changes of TBS buffer for 5 mins
each.
9. Optimally diluted primary antibody was then used to incubate the
slides for 60 mins.
10. Then the slides were washed in 2 changes of TBS buffer for
5 mins each.
11. Then incubation with post primary for 30 mins
12. Then the slides were washed in 2 changes of TBS buffer for
5 mins each.
13. Then incubation with novolink polymer for 30 mins
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14. Then the slides were washed in 2 changes of TBS buffer for
5 mins each.
15. Then peroxidase activity was developed with DAB working
solution.
16. The slides were then rinsed in water, counterstained in
hematoxylin, washed in water, dehydrated, cleared and mounted
to be examined.
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Method of studying Maspin expression
The immunoreactivity to maspin was identified by staining of
the cytoplasm. 100 cells were randomly selected and counted from
5 representativefields.
 A four tier grading system was used to study the intensity of
expression:
  1. Negative (-)  0-5%
  2. Weakly-positive (+),   6-25%
  3.  Moderately-positive (++), 26-50%
  4.  Strongly-positive (+++), 51-100%.
This grading system was  used in the study by Zheng et al [45].
Figure 6 :Colorectal Adenocarcinoma (H & E, 10 X)
Figure 7 :Colorectal Adenocarcinoma (H & E, 40 X)
Figure 8 :Maspin expression (3 +) in colorectal adenocarcinoma –
(10 X)
Figure 9 :Maspin Expression (3 +) in colorectal Adenocarcinoma
(40 X)
Figure 10 :Adenoma – (H & E, 10 X)
Figure 11 :Adenoma – (H & E, 40 X)
Figure 12 :Maspin Expression (3 +) in Adenoma – (10 X)
Figure 13 :Maspin Expression (3 +) in Adenoma – (40 X)
Figure 14 :Ulcerative Colitis (H & E, 10 X)
Figure 15 :Maspin Expression (1 +) in Ulcerative colitis (40 X)
Figure 16 :Non Specific colitis – (H & E, 10 X)
Figure 17 :Maspin Expression (1 +) – Non specific colitis (10 X)
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OBSERVATION AND RESULTS
70 cases were selected representing different colorectal
neoplastic and non neoplastic conditions. The following indicates the
distribution of the cases.
Table 5
Distribution of Cases
Case Number
1. Normal colonic mucosa 10
2.  Non specific colitis 10
3. Ulcerative colitis 10
4. Adenocarcinoma including 4
cases ofAdenoma with
malignant transformation
40
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Immunohistochemical analysis and results
Immunohistochemistry was done for all the above 70 cases and the
following results were tabulated.
Table 6
Significance of maspin expression in  non neoplastic and neoplastic
colorectal diseases
Diseases n 0 1+ 2+ 3+ Percentagepositivity
Normal colonic
mucosa
10 8 2 0 0 20%
Ulcerative colitis 10 4 3 3 0 60%
Non specific colitis 10 8 2 0 0 20%
Adenocarcinoma 40 4 15 13 8 90%
Chi-Square Test P-Value
Fisher’s Exact Chi-Square test <0.001
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 Thus significant difference in expression of maspin was
found from normal colonic mucosa to ulcerative colitis to
adenocarcinoma.
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This is similar to the findings in the study by Payne et al[46] which
showed a significant difference in maspin expression in neoplastic and
non neoplastic colorectal diseases.
Table 7
Study by Payne et al
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 The inference from this  table shows that  there is  a  significant
difference in the expression of maspin in different conditions with it
being the highest in colorectal cancers compared to other conditions
.More number of cases showed +3 expression as we moved from
ulcerative colitis to adenoma to carcinoma. This is comparable  with the
findings of  Payne et al  in their study of maspin which is a
deoxycholate-inducible, anti-apoptotic stress-response protein. Its
expression is modified in colon carcinogenesis.This is also consistent
with the study of Cao et al[41].They had assessed 25 cases of
colorectal carcinoma showing 88% positivity of maspin and 51 cases
of active chronic IBD showing 92 % positivity.
61
Table 8
Comparison table with other studies
Study Year Inference –p value
Payne et al 2011  less than 0.05
Cao et al 2005 Less than 0.05
Song et al [47] 2002 Less than 0.05
Fung et al 2010 Less than 0.05
Present study 2012-2013 Less than 0.05
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Table 9
Relationship between maspin expression and age of the patient
Age Number 0 1+ 2+ 3+
Less than
20 yrs
1 1 0 0 0
20- 50
years
31 10 11 7 3
More than
50 yrs
28 5 9 9 5
Chi-Square Test P-Value
Fisher’s Exact Chi-Square
test 0.516
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This shows that no significant difference was present between
maspin expression and the age of the patient which is also an important
prognostic factor .According to certain studies, young and very old age
groups were at high risk for aggressive course of the
disease[48,49,50,51].But our finding was found to be consistent with the
study by Pasz- Walczak G et al[52] that maspin expression did not co-
relate with age of the patient.
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Table 10
Comparison table with other studies.
Study Year Inference
1. Pasz- Walczak G
et al
2010 More than 0.05
2. Present study 2012-2013 More than 0.05
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Table 11
Relationship between maspin expression and sex of the patient
Sex Number 0 1+ 2+ 3+
Male 47 15 18 10 4
Female 13 1 2 6 4
Chi-Square Test P-Value
Fisher’s Exact Chi-Square test 0.018
66
This table shows that the expression of maspin significantly
correlated with  the sex of the patient. According to the study by Griffin
et al[48] males are at higher risk for an aggressive course of the diseases
compared to females.Our study was comparable with the following
study by boltze et al[53] in which significant difference was found in the
expression of maspin and the sex of the patient, thus showing
increased expression  in  males .
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Table 12
Comparison table with other studies
Study Year Inference –P value
1. Boltze et al 2005 Less than 0.05
2. Present study 2012-2013 Less than 0.05
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Table 13
Site distribution of  neoplastic and non neoplastic diseases
Diseases number
Right sided
lesions
Left sided
lesions
Non specific
colitis
10 7 3
Ulcerative colitis 10 4 6
Adenocarcinoma 40 10 30
 This table shows that left sided lesions are more common
compared to right sided lesions in adenocarcinomas. This is comparable
with the following studies.
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Table 14
Comparison table with other studies for neoplastic diseases[54,55,56]
Study Year
Inference – most
common site
Peedikayil et al 2009 Rectum
Chattar cora et al 1976- 1995 Rectum
Qing SH et al 2003 Rectum
Present study 2012-2013 Rectum
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Table 15
Expression of maspin in right sided and left sided lesions in both
neoplastic and non neoplastic diseases
Site Number 0 1+ 2+ 3+
Right side 21 7 9 3 2
Left side 39 9 11 13 6
Chi-Square Test P-Value
Fisher’s Exact Chi-Square test 0.306
This table shows that there is no significant difference
between maspin expression and the site of the disease.
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 This is contradication with the studies  by Snoeren et al[57] and
Fung et al which stated that right sided lesions had a higher expression
compared to left sided lesions.
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Table 16
Comparison table with other studies
Study Year P Value
1. Snoeren et al 2012 Less than 0.05
2. Fung et al 2010 Less than 0.05
3. Present study 2012-2013 More than 0.05
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Table 17
Significance of maspin expression based on tumor size
Tumor size n 0 1+ 2+ 3 +
< 4 CM 9 2 5 2 0
>4 CM 31 2 10 11 8
Chi-Square Test P-Value
Fisher’s Exact Chi-Square test 0.110
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This table shows that there is no significance between
expression of maspin and the tumor size. This was comparable with the
following studies.
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The following table is a study by Zheng et al.
Table 18
Significance of Maspin expression and tumor size  by Zheng et al.
Tumor size n 0 1+ 2+ 3+ Percentage
positivity
P value
Less than 4 47 1 7 6 33 98 > 0.05
More than 4
cms
72 5 14 15 38 93
This table shows that there is no significance  between the
tumor size  and the expression of maspin. This is comparable with the
findings of Zheng et al
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Table 19
Comparison table with other studies
Study Year and inference
Zheng et al 2007,P >0.05
Present study 2012-2013, P>0.05
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Table 20
Significance of maspin expression and depth of invasion
DEPTH OF
INVASION N 0 1+ 2+ 3+
ABOVE
SUBMUCOSA 9 2 5 2 0
MUSCULARIS 12 1 7 4 0
BELOW
SUBSEROSA 19 1 3 7 8
Chi-Square Test P-Value
Fisher’s Exact Chi-Square test 0.010
78
 This table shows that there is a significant difference in the
expression of maspin as the depth of invasion increases.This is
consistent with the findings of Umekita et al. This study showed
significant difference in the expression of maspin as the depth of
invasion varies. Thus the conclusion drawn from this table is that
increased expression of maspin was associated with increasing
depth of invasion of the tumor.
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Table 21
Study by Umekita et al
Table 22
Comparison table with other Studies
Study Year Inference
Umekita et al
Pasz Walczak et al
2006
2010
P<0.05
P<0.05
Present study 2012-2013 P <0.05
Maspin expression  Positive             Negative
? Depth of invasion
? T1, T2                                     3                   17
? T3, T4                                   66                  18
? P value – less than 0.0001
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Table 23
Significance of maspin expression and lymphovascular invasion
Lymphovascular
INVASION N 0 1+ 2+ 3+
LYMPHATIC OR
VENOUS INVASION 6 0 3 3 0
LYMPHATIC AND
VASCULAR
INVASION
5 1 0 0 4
Chi-Square Test P-Value
Fisher’s Exact Chi-Square test 0.002
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This table shows that there is a significant difference in the
expression of maspin as there is variation in the lymphovascular
invasion. This is in contradiction with the studies by Zheng et al and
Umekita et al. But in the study by Pasz-Walczak G et al increased
maspin expression was associated with vascular invasion. This is
comparable with our study showing increased maspin expression
associated with presence of lymphatic and vascular invasion.
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Table 24
Study by Zheng et al
?
?
?
?
?
?
?
Table 25
Study by Umekita et al
? Vascular invasion      positive         negative
? present                           45                   19
? absent                             24                   16
? P value – 0.278
? Local invasion via vessels>0.05
 n     0       1+    2+   3+     percentage
–  ( negative) 30   1       6       4     19       97
? Lymphatic or
 venous invasion         34   2     4       7     21       94
? Lymphatic &
venous invasion          55    3     11      10    31       95
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Table 26
Comparison table with other studies
Study Year Inference
Zheng et al 2007 P >0.05
Umekita et al 2006 P>0.05
Pasz walczak et al 2010 P<0.05
Present study 2012-2013 P<0.05
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Table 27
Significance of maspin expression based on differentiation of tumor
DIFFERENTIATION N 0 1+ 2+ 3+
WELL
DIFFERENTIATED 9 0 5 4 0
MODERATELY
DIFFERENTIATED 26 3 8 8 7
POORLY
DIFFERENTIATED 5 1 2 1 1
Chi-Square Test P-Value
Fisher’s Exact Chi-Square test 0.423
85
This  table  shows  that  there  is  no  significant  difference  in
expression of maspin  with variation in tumor differentiation .
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Table 28
Significance of maspin expression in the presence of liver metastasis
LIVER
METASTASIS N 0 1+ 2+ 3+
PRESENT 2 1 0 0 1
ABSENT 38 3 15 13 8
Chi-Square Test P-Value
Fisher’s Exact Chi-Square test 0.095
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This table shows that there is no significant difference in the
expression of maspin in the presence of liver metastasis.
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Table 29
Significance of maspin expression in the presence of lymph node
metastasis
LYMPH NODE
METASTASIS N 0 1+ 2+ 3+
PRESENT 9 1 6 2 0
ABSENT 31 3 9 10 8
Chi-Square Test P-Value
Fisher’s Exact Chi-Square test 0.144
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This table shows that there is no significant difference in the
expression of maspin in the presence or absence of lymph node
metastasis.These findings were consistent with the studies by Umekita
et al where no significant co-relation was observed between maspin
expression and liver metastasis, lymph node metastasis or tumor
differentiation.Whereas in Zheng et al significant correlation was found
between maspin expression and liver metastasis whereas that of tumor
differentiation and lymph node metastasis the results were same as our
study.
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Table 30
Study by Zheng et al
? Lymph node metastasis >0.05                               n          0        1+   2+   3+
? –                                     49       2       10     9     28
? +                                     70       4       11     12     43
? Liver metastasis <0.05
? –                                     96      11       13     14     58
? +                                     33       5        8        7      13
? Differentiation >0.05
? Well-differentiated     68      2        11     13    42
? Moderately-
? differentiated               45       3        10     5     27
? Poorly-differentiated 6 1      0         3      2      8
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Table 31
Study by Umekita et al
? Maspin expression          Positive             Negativep value
? Lymph node metastases
? present                                 34                  11
? absent                                   35                  200.287
Differentiation
? well                                  41                      27                      0.198
? moderate                       24                   7
? Poor                                  4 1
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Table 32
Comparison table with other studies
Study Year Parameter Inference
Zheng et al
Fung et al
Snoeren et al
2007
2010
2013
1.Lymph node metastasis
2.Differentiation
3.Liver metastasis
1.Tumor differentiation
1.Tumor differentiation
1.P value >0.05
2. >0.05
3.<o.o5
1.<0.05
1.<0.05
Umekita et al
Jiang Tao Ni
et al[58]
Pasz Walczak
et al
2006
2009
2010
1.Lymph node metastasis
2.Tumor differentiation
1.Tumor differentiation
1.Tumor differentiation
1. >0.05
2. >0.05
1.>0.05
1.<0.05
Present study 2012-
2013
1.Lymph node metastasis
2.Tumor differentiation
3.Liver metastasis
1. >0.05
2. >0.05
3. >0.05
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Table 33
Maspin expression and survival rates
Maspin expression Number Survival rates
0 16 93.75%
1+ 20 85%
2+ 16 81%
3+ 8 50%
Chi-Square Test Value P-Value
Trend Chi-Square 5.491 0.019
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This table shows that there is a significant difference in the
expression of maspin and survival rates of patients with both
neoplastic and non neoplastic colorectal diseases.
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
70.0%
80.0%
90.0%
100.0%
0 1+ 2+ 3+
93.8%
85.0%
81.0%
50.0%
Pe
rc
en
ta
ge
Expression
Maspin expression based on survival rates
Figure - 28
95
Table 34
Comparison table with other studies
Study Year
Inference – survival rates
and maspin expression
Gurzu et al 2013 Poor survival
Pasz walczak et al 2010
No association with
survival
Present study 2012-13 Poor survival
Our study is thus comparable with the study by Gurzu
et al which shows that higher the expression of maspin, poor is the
survival.
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DISCUSSION
Colorectal carcinomas are common in people with western
type of diet. Hence the incidence is more  in individuals adopting a
western lifestyle and slowly the occurrence in increasing in the Asian
population compared to the western population. [59]
 In this study, several clinicopathological parameters were
analysed in the selected 70 cases and immunohistochemical expression
of maspin was studied in different clinicopathological features of  the
cases includedand it was compared with different studies.
Of  the 70 cases, 10 were of normal colonic mucosa,10 cases
were  ulcerative colitis, 10 cases were non specific colitis and remaining
40 cases were adenocarcinomas which included 4 cases of adenoma
with malignant transformation.
Maspin is a 42 kDa protein which belongs to the family of
serine peptidase inhibitor proteins. Early experiments with maspin in
mammary tissue indicated that it acted as a tumor suppressor. However,
maspin does not undergo the S (stressed) to R (relaxed) conformational
transition which characterizes active serpins. Thus, the mechanism with
which it exerts its tumor suppressor activity has been actively sought.
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One of the mechanisms which was proposed to explain the tumor-
suppressive functions of maspin in noncolon-derived cells is that it
sensitizes cells to apoptosis, thus preventing the clonal expansion of
preneoplastic cells with DNA damage. In contrast to the mammary
tissue, maspin expression in colon epithelial tissue appears to be related
to increased colon cancer risk and decreased patient survival. High
maspin expression is associated with neoplastic transformation and high
tumor grade .
In our study increased maspin expression was associated with
male sex, increasing  depth of invasion and presence of lymphatic and
vascular invasion thus showing increased expression with increase in
aggressiveness of colorectal cancers. No significance was found to be
associated with increasing tumor size or differentiation of the tumor or
presence of liver metastasis. Our study is comparable with other parallel
studies where expression of maspin was studied in colorectal carcinoma
and significant co relation with tumor progression and aggressiveness
was found .Thus maspin expression was correlated with poor prognosis
in colorectal carcinomas and a significant difference in expression was
found from normal colonic mucosa to chronic active IBD to carcinoma.
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Table 35
Summary table of the findings in the study
Study parameter – maspin
expression with respect to -
P value
Age Not significant
Sex Significant
Site Not significant
Normal colonic mucosa to
ulcerative colitis to carcinoma
Significant
Tumor size Not significant
Depth of invasion Significant
Differentiation Not significant
Lymphovascular invasion Significant
Liver metastasis Not significant
Lymph node metastasis Not significant
Survival rates Significant
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All these findings were compared with appropriate studies and
conclusions were drawn.
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SUMMARY AND CONCLUSION
70 cases of colorectal diseases were selected for the study
from the period 2012-2013. Among these cases
2.10 cases belonged to non specific colitis ,
2.10 cases to ulcerative colitis
3. 40 cases to colorectal carcinomas
4. 10 were of normal colonic mucosa which served as controls.
Immunohistochemical expression of maspin was studied in all
these cases. Maspin, a serine protease inhibitorhas been found to be
involved in processes that are important to  tumor growth and metastasis
such as cell  invasion ,apoptosis and angiogenesis.
The expression of maspin with various clinicopathological
parameters  was  analysed  and  its  importance  as  a  prognostic  factor  was
assessed.
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Increased Maspin Expression  was found to be associated with
1. Male sex
2. Increasing depth of tumor
3.  Presence of Lymphatic and vascular invasion
4. Increased expression in colorectal carcinoma compared to
normal colonic mucosa, non specific colitis and ulcerative
colitis
4. Poor survival
All these findings were  comparable with several studies.
The expression of maspin was not significant in the following
parameters
 1.  Tumor differentiation
 2.  Liver metastasis
 3.  Tumor size.
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Thus in our study maspin was found to be associated with
increasingaggressiveness of colorectal cancers. In a study by Dietmeir
et al  maspin expression was found to be associated with better response
to 5-Fluorouracil based therapy[60] . Thus its expression can be studied in
aggressive tumors to decide the line of treatment.
Hence to conclude, immunohistochemical analysis of maspin
can be done in non neoplastic colorectal diseases to assess any disease
flare and in colorectal diseases to assess its aggressiveness and decide
the line of treatment.
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BIOPSY NO AGE SEX SPECIMEN TYPE Diagnos is  -  Si te Tumor s ize Depth of  invas ion Lymphatic  (L)vascular(V)  invas ion Di fferentiation Liver  Metastas isLymph Node metastas isMaspin  Express ion
3863/12 50 M Biopsy  Adenocarcinoma-Cecum < 4 cms Above submucosa  - Moderate Absent Absent 1+
1007/13 50 M Biopsy Adenocarcinoma-Rectum < 4 cms Above submucosa  - Wel l Absent Absent 2+
2298/12 48 M Biopsy Adenocarcinoma-Rectum < 4 cms Above submucosa  - Moderate Absent Absent 1+
2819/12 74 M Biopsy Adenocarcinoma-Sigmoid  colon < 4 cms Above submucosa  - Moderate Absent Absent 1+
3750/12 55 M Biopsy Adenocarcinoma - Rectum < 4 cms Above submucosa  - Moderate Absent Absent  -
1127/13 66 F Biopsy Adenocarcinoma - Rectum < 4 cms Above submucosa  - Wel l Absent Present 1+
1117/13 50 M Biopsy Adenocarcinoma -Sigmoid  colon < 4 cms Above submucosa  - Wel l Absent Present 1+
4302/12 74 M Biopsy Adenocarcinoma-Rectum < 4 cms Above submucosa  - Poorly Absent Absent  -
4240/12 72 F Proctocolectomy Adenocarcinoma-Rectum > 4 cms Below  subserosa  - Moderate Absent Absent 3+
3818/12 27 F Proctocolectomy Adenocarcinoma-Rectum > 4 cms Muscularis L + Wel l Absent Absent 1+
503/12 51 M Hemicolectomy Adenocarcinoma-Hepatic  Flexure > 4 cms Below  subserosa   L +, V + Moderate Present Absent  -
1696/12 57 F Proctocolectomy Adenocarcinoma -Rectum > 4 cms Below  subserosa   L +, V + Poorly Absent Absent 3+
3404/12 52 M Proctocolectomy Adenocarcinoma-Rectum > 4 cms Below  subserosa L + Moderate Absent Absent 2+
3785/12 75 M Hemicolectomy Adenocarcinoma-Cecum > 4 cms Muscularis  - Wel l Absent Present 1+
3547/12 72 F Proctocolectomy Adenocarcinoma-Rectum > 4 cms Below  subserosa  - Moderate Absent Absent 2+
3991/12 50 M Hemicolectomy Adenocarcinoma-Sigmoid  colon > 4 cms Muscularis  - Moderate Absent Present  -
1303/12 60 M Proctocolectomy Adenocarcinoma-Rectum > 4 cms Below  subserosa L + Moderate Absent Absent 2+
892/12 55 M Hemicolectomy Adenocarcinoma-Cecum > 4 cms Muscularis  - Poorly Absent Absent 1+
2863/12 70 M Hemicolectomy Adenocarinoma-Hepatic  flexure > 4 cms Below  subserosa   L +, V + Moderate Absent Absent 3+
4355/12 65 M Proctocolectomy Adenocarcinoma-Rectum > 4 cms Muscularis  - Moderate Absent Present 1+
5969/12 60 M Proctocolectomy Adenocarcinoma-Rectum > 4 cms Below  subserosa L + Moderate Absent Absent 1+
2177/12 57 M Hemicolectomy Adenocarcinoma-Hepatic  Flexure > 4 cms Muscularis L + Moderate Absent Present 1+
5861/12 55 M Proctocolectomy Adenocarcinoma-Rectum > 4 cms Muscularis  - Moderate Absent Absent 1+
3077/12 20 M Proctocolectomy Adenocarcinoma-Rectum > 4 cms Below  subserosa  - Moderate Absent Present 1+
1573/12 42 M Proctocolectomy Adenocarcinoma-Rectum > 4 cms Below  subserosa   L +, V + Moderate Present Absent 3+
4293/12 41 M Proctocolectomy Adenocarcinoma-Rectum > 4 cms Below  subserosa   L +, V + Moderate Absent Absent 3+
4175/12 65 M Proctocolectomy Adenocarcinoma-Rectum > 4 cms Below  subserosa  - Poorly Absent Absent 1+
3195/12 48 F Hemicolectomy Adenocarcinoma-Ascending colon > 4 cms Muscularis L + Moderate Absent Absent 2+
2378/12 57 M Hemicolectomy Adenocarcinoma-Ascending colon > 4 cms Below  subserosa  - Moderate Absent Present 2+
3894/12 65 M Hemicolectomy Adenocarcinoma-Descending colon > 4 cms Below  subserosa  - Moderate Absent Present 2+
4388/12 60 F Hemicolectomy Adenocarcinoma-Ascending colon > 4 cms Below  subserosa  - Moderate Absent Absent 3+
589/12 43 M Proctocolectomy Adenocarcinoma-Rectum > 4 cms Below s ubserosa - Moderate Absent Absent 3+
618/12 65 M Proctocolectomy Adenocarcinoma-Rectum > 4 cms Muscularis  - Wel l Absent Absent 2+
1367/12 70 M Proctocolectomy Adenocarcinoma-Rectum > 4 cms Muscularis  - Wel l Absent Absent 2+
1498/12 42 M Hemicolectomy Adenocarcinoma-Ascending colon > 4 cms Muscularis  - Wel l Absent Absent 1+
3580/12 50 M Biopsy Adenoma-Sigmoid colon < 4 cms Below s ubserosa - Moderate Absent Absent 2+
3547/12 72 F Biopsy Adenoma-Rectum < 4 cms Below s ubserosa - Moderate Absent Absent 3+
3193/12 56 M Total Proctocolectomy Adenoma-Rectum > 4 cms Below s ubserosa - Poorly Absent Absent 2+
4102/12 72 F Proctocolectomy Adenoma-Rectum < 4 cms Muscularis  - Wel l Absent Absent 2+
749/12 40 M Biopsy Non Speci fic  col i ti s -Descending  colon -  -  -  -  -  -  -
809/12 47 M Biopsy Non Speci fic  col i ti s -hepatic  flexure  -  -  -  -  -  -  -
847/12 47 M Biopsy Non Speci fic  col i ti s -hepatic  flexure  -  -  -  -  -  -  -
690/12 26 M Biopsy Non Speci fc col i ti s -Cecum   -  -  -  -  -  -  -
506/12 30 M Biopsy Non Speci fic  col i ti s -hepatic  flexure  -  -  -  -  -  - 1+
2296/12 30 M Biopsy Non Speci fic  col i ti s -Rectum  -  -  -  -  -  -  -
749/12 40 M Biopsy Normal colonic mucosa  -  -  -  -  -  -  -
809/12 47 M Biopsy Normal colonic mucosa  -  -  -  -  -  -  -
847/12 47 M Biopsy Normal colonic mucosa  -  -  -  -  -  -  -
690/12 26 M Biopsy Normal colonic mucosa  -  -  -  -  -  -  -
506/12 30 M Biopsy Normal colonic mucosa  -  -  -  -  -  - 1+
2296/12 30 M Biopsy Normal colonic mucosa  -  -  -  -  -  -  -
3186/12 51 M Biopsy Ulcerative  col i ti s -Rectum  -  -  -  -  -  -  -
4281/12 37 F Biopsy Ulcerative  col i ti s -Cecum  -  -  -  -  -  - 2+
759/12 45 F Biopsy Ulcerative  col i ti s -Rectum  -  -  -  -  -  - 2+
1531/12 18 M Biopsy Ulcerative  col i ti s -Rectum  -  -  -  -  -   -  -
3059/12 26 M Biopsy Ulcerative  col i ti s -Cecum  -  -  -  -  -  - 1+
964/12 30 M Biopsy Ulcerative  col i ti s -Cecum  -  -  -  -  -  -  -
3186/12 51 M Biopsy Ulcerative  col i ti s -Rectum  -  -  -  -  -  -  -
4281/12 37 F Biopsy Ulcerative  col i ti s -Rectum  -  -  -  -  -  - 2+
3059/12 26 M Biopsy Ulcerative  col i ti s -Transverse  colon -  -  -  -  -  - 1+
3059/12 26 M Biopsy Non Speci fic  col i ti s -Rectum  -  -  -  -  -  - 1+
1499/12 39 M Biopsy Non Speci fic  col i ti s -Cecum  -  -  -  -  -  - 1+
1572/12 42 F Biopsy Non Speci fic  col i ti s -Cecum  -  -  -  -  -  -  -
4202/12 25 M Biopsy Non Speci fic  col i ti s -Sigmoid  -  -  -  -  -  -  -
2690/12 26 M Biopsy Non Speci fic  col i ti s -Ascending  colon -  -  -  -  -  -  -
1499/12 39 M Biopsy Normal colonic mucosa  -  -  -  -  -  - 1+
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1572/12 42 F Biopsy Normal colonic mucosa  -  -  -  -  -  -  -
2690/12 26 M Biopsy Normal colonic mucosa  -  -  -  -  -  -  -
4202/12 25 M Biopsy Normal colonic mucosa  -  -  -  -  -  -  -
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